Longevity & Aging · Metabolic & Cardiometabolic
ApoB apolipoprotein B or LDL particle number predicts ASCVD risk better than LDL-C alone especially when discordant
In plain terms: Is ApoB a better heart-attack risk predictor than standard LDL cholesterol?
Part of: • ApoB & Lipid Longevity
Yes — ApoB captures atherogenic particle number and outperforms LDL-C when the two disagree, though absolute gain over non-HDL-C is modest and it does not overturn LDL-C's causal role.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
ApoB measures atherogenic particle number and outperforms LDL cholesterol where the two disagree: in 68,616 statin-treated patients, apoB in excess of what LDL-C predicted carried extra risk. The gain over non-HDL-C is modest rather than decisive, and findings that small-dense LDL adds information too suggest apoB is not uniquely superior among particle measures.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Li TY, Zhu P, Song Y, Tang XF, Gao Z, Gao RL, Yuan JQ 2023 · J Geriatr Cardiol | observational | mixed | moderate | In statin-treated CAD patients, apoB and non-HDL-C showed broadly similar discrimination for recurrent myocardial infarction. |
| Pan W, Lu X, Zhou Z, Liu J, Zhang S, Huang H, He Y, Deng J, Ling Y, Ruan X, Jing L, Zhang W, Chen S, Liao X, Chen J, Zhuang X, Liu Y 2026 · Lipids Health Dis | observational | supports | high | Pooled cohort (68,616 statin-treated CAD patients, UK Biobank validation) found excess apoB (measured minus LDL-C-predicted apoB) independently predicted all-cause mortality (aHR 1.12) and CV mortality (aHR 1.24) per 1-SD, persist |
| Wang B, Nurmohamed NS, Kraaijenhof JM, Li D 2026 · Eur J Prev Cardiol | observational | supports | moderate | ApoB-defined particle burden added risk stratification beyond LDL-C across the LDL-C distribution, supporting a particle-number axis over cholesterol mass alone. |
| Zubiran R, Sampson M, Wolska A, Remaley AT 2025 · Arterioscler Thromb Vasc Biol | observational | mixed | high | UK Biobank analysis found estimated small-dense LDL-C added risk information, indicating apoB is not uniquely superior among particle-based markers. |
| Li C, He K, Yang Y, Li K, Chen M, Wang L, Gao Y, Xu X 2023 · Rev Cardiovasc Med | observational | supports | low | In statin-treated post-CABG ACS patients (n=468), discordant high-non-HDL-C/low-LDL-C carried elevated MACE risk (HR=2.44) versus concordant-low, showing non-HDL-C captures residual risk LDL-C misses. |
| Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT, Sabatine MS 2022 · JAMA Cardiol | observational | supports | high | In FOURIER and IMPROVE-IT, apoB particle number predicted myocardial infarction better than LDL-C or triglyceride content. |
| Rehman 2026 · Eur Heart J | observational | mixed | moderate | Even apoB underestimates risk when remnants/Lp(a) are high, requiring a risk-weighted apoB metric — apoB is better than LDL-C but not a complete single marker. |
| Genedy N, Zouwail S 2026 · J Clin Lipidol | observational | supports | low | Hypothesis-generating HeFH cohort: apoB/LDL-C discordance flagged higher ASCVD risk despite apparently controlled LDL-C, but sparse and preliminary. |
| Hu F, Wu R, Zhao X, Zhao Y, Zhou J, Hu B, Li A, Sun Y 2025 · Transl Stroke Res | observational | supports | moderate | ApoB predicted recurrent ischemic stroke with greater discriminatory ability (AUC 0.732) than LDL-C (0.685). |
| Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A 2014 · J Am Heart Assoc | meta-analysis | supports | high | In statin RCTs, on-treatment apoB reduction related more closely to event reduction than LDL-C or non-HDL-C, favoring apoB as the treatment-adequacy marker. |
| Sun X, Guo L, Lv H, Zhang X, Wu C, Liu X 2026 · Front Cardiovasc Med | observational | supports | moderate | Cross-sectional study (n=4,938) found ApoB (OR 1.12) and ApoB/ApoA1 ratio (OR 1.14) independently associated with retinal arteriosclerosis, a microvascular ASCVD-related surrogate, after adjustment for confounders. |
| Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD 2011 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Head-to-head meta-analysis of LDL-C, non-HDL-C and apoB found apoB the single most potent marker of cardiovascular risk among the three. |
| Sniderman AD, Lamarche B, Contois JH, de Graaf J 2014 · Curr Opin Lipidol | observational | supports | moderate | Narrative review, no new data: 'The evidence, to date, consistently demonstrates that apolipoprotein B and LDL particle numbers are more accurate indices of cardiovascular risk than LDL-C or non-HDL-C.' Re-describes discordance analyses (e.g. Framingham, MESA, Women's Health Study) held directly - zero weight. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.